Company: IMNN
Filing Date: 2025-05-13
Form Type: S-1/A
Source: 0001641172-25-009814
Chunk: 13

Company: Imunon, Inc.
Filing Date: 2025-05-13
Form: S-1/A
Chunk 13
---
 development studies. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company has entered into a first-in-human study of its COVID-19 booster vaccine (IMNN-101). We will continue to leverage these modalities and to advance the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions.

Recent Developments

On March 24,
2025, we issued a press release announcing finalization of our Phase 3 study design for IMNN-001, a treatment for women with newly
diagnosed advanced ovarian cancer, and that the U.S. Food and Drug Administration is aligned with the protocol for the Phase 3 pivotal trial, called OVATION 3, of our lead candidate IMNN-001.

On May 12, 2025, the Company entered into an exchange agreement (the “ Exchange Agreement”) with the holders (the “Existing Warrant Holders”) of certain warrants of the Company (the “ Existing Warrants”) issued on August 1, 2024, which are exercisable for an aggregate of 5,000,000 shares of Common Stock. Pursuant to the terms of the Exchange Agreement, the Company will issue to the Existing Warrant Holders an aggregate of 2,921,000 shares of Common Stock (the “ Warrant Exchange Shares”), on a one-for-one basis, in exchange for shares issuable under the Existing Warrants (the “ Warrant Exchange”), in reliance on an exemption from registration provided by Section 3(a)(9) of the Securities Act. The Warrant Exchange is expected to close on May 13, 2025. The number of Warrant Exchange Shares that will be issued pursuant to the Exchange Agreement will represent 19.98% of the shares of Common Stock outstanding as of the date of the Exchange Agreement.

Corporate Information

We were founded in 1982 and are a Delaware corporation. Our principal executive offices are located at 997 Lenox Drive, Suite 100, Lawrenceville, NJ 08648. Our telephone number is (609) 896-9100. Our website is www.imunon.com. The information contained on or that can be accessed through our website is not incorporated by reference into this prospectus, and you should not consider information on our website to be part of this prospectus or in deciding to purchase our Common Stock